Eli Lilly Bid to Upset Age-Bias Class Test Meets Leery 7th Cir.
Eli Lilly & Co. faced a skeptical Seventh Circuit Tuesday in arguing a lower court used a misplaced two-step process when it ...
MarketBeat on MSN15h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Morningstar14d
Health Care Slides After Lilly Warning - Health Care Roundup
Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...
NBC New York14d
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight ... Trump administration. Eli Lilly said Monday it would acquire ...
NBC Connecticut14d
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...